Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 7/20 | 0.61 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.45 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | GALR3 | O60755 | 2/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TGM2 | P21980 | 1/20 | 0.32 |
| ▸ | PPOX | P50336 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386647 | 1.00 | CES1 (0.61) | CES1SIRT2SIRT1SIRT3MAPT | |
| SCHEMBL16279415 | 1.00 | CES1 (0.61) | CES1SIRT2SIRT1SIRT3MAPT | |
| SCHEMBL30876329 | 1.00 | CES1 (0.61) | CES1SIRT2SIRT1SIRT3MAPT | |
| SCHEMBL19481154 | 1.00 | CES1 (0.61) | CES1SIRT2SIRT1SIRT3MAPT | |
| SCHEMBL11029570 | 0.83 | CES1 (0.63) | CES1SIRT2SIRT1SIRT3MAPT | |
| SCHEMBL6315804 | 0.83 | CES1 (0.63) | CES1SIRT2SIRT1SIRT3MAPT | |
| SCHEMBL6555757 | 0.79 | CES1 (0.56) | CES1SIRT2SIRT1SIRT3MAPT | |
| SCHEMBL6426529 | 0.76 | CES1 (0.49) | CES1SIRT2SIRT1SIRT3MAPT | |
| SCHEMBL1248801 | 0.76 | CES1 (1.00) | CES1SIRT2SIRT1SIRT3MAPT | |
| SCHEMBL6316266 | 0.75 | CES1 (0.51) | CES1SIRT2SIRT1SIRT3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3565586-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | Iovance Biotherapeutics, Inc. (US) | 2019-11-13 | — | — | EP | claimed |
| WO-2018129336-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2018-07-12 | — | — | WO | claimed |
| US-20170299609-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS WITH SK CHANNEL ACTIVATORS | WRIGHT STATE UNIVERSITY (US) | 2017-10-19 | — | — | US | claimed |
| US-6969729-B2 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2005-11-29 | — | — | US | claimed |
| EP-1135123-B1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH AS (DK) | 2004-12-29 | — | — | EP | claimed |
| WO-2004039409-A2 | COMPOSITION COMPRISING ACTIVATORS OF IK POTASSIUM CHANNELS AND CALCINEURIN ANTAGONISTS AND USE THEREOF | SWITCH BIOTECH AG (DE) | 2004-05-13 | — | — | WO | claimed |
| US-20030114513-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S | 2003-06-19 | — | — | US | claimed |
| JP-2002531498-A | — | — | 2002-09-24 | — | — | JP | claimed |
| US-20020016354-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2002-02-07 | — | — | US | claimed |
| EP-1135123-A1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH A/S (DK) | 2001-09-26 | — | — | EP | claimed |
| WO-2000033834-A1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-15 | — | — | WO | claimed |
| US-12629356-B2 | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-3565586-B1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS INC (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20240366627-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-11-07 | — | — | US | disclosed |
| US-20240216343-A1 | ENDOTHELIAL IK AND SK CHANNEL ACTIVATION TO TREAT PULMONARY HYPERTENSION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2024-07-04 | — | — | US | disclosed |
| US-20030114513-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S | 2003-06-19 | — | — | US | disclosed |
| WO-2002053171-A2 | USE OF INTERMEDIATE-CONDUCTANCE POTASSIUM CHANNELS AND MODULATORS FOR THE DIAGNOSIS AND TREATMENT OF ILLNESSES HAVING DISTURBED KERATINOCYTE ACTIVITY | SWITCH BIOTECH AKTIENGESELLSCHAFT (DE) | 2002-07-11 | — | — | WO | disclosed |
| US-20020016354-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2002-02-07 | — | — | US | disclosed |
| EP-1135123-A1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH A/S (DK) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000033834-A1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629356-B2 | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof | PBK, IL2, KCNN3 | CES1 3357/4885SIRT2 2601/4885SIRT1 3723/4885 |
| US-20030114513-A1 | Use of isatin derivatives as ion channel activating agents | KCNN3, KCNJ2, KCND2 | CES1 2434/4885SIRT2 2347/4885SIRT1 2502/4885 |
| US-20240366627-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | CES1 3739/4885SIRT2 326/4885SIRT1 272/4885 |
| US-20170299609-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS WITH SK CHANNEL ACTIVATORS | KCNN3, KCNN2, KCNN1 | CES1 4169/4885SIRT2 1261/4885SIRT1 754/4885 |
| US-20020016354-A1 | Use of isatin derivatives as ion channel activating agents | KCNN3, KCNJ2, KCND2 | CES1 2526/4885SIRT2 2210/4885SIRT1 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.